News

Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA), according to a single-center study in Iran. While the safety profiles of the two therapies were comparable, treatment with rituximab was more effective, the study found. Specifically, about 90% of…

Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that predict patient outcomes better than classifying patients according to granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two AAV subtypes. The new disease clusters, identified with advanced artificial intelligence (AI)…

Nearly one year of treatment with rituximab was superior to traditional immunosuppressive medications at helping people with ANCA-associated vasculitis (AAV) achieve remission after a severe relapse, an analysis of data from a multicenter study in Japan has found. Such superiority was not observed at six months of treatment,…

The combination antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) may help prevent serious infections for people with granulomatosis with polyangiitis (GPA) who are taking the immunosuppressant rituximab, a study of U.S. data shows. Preventive treatment, or prophylaxis, with TMP-SMX in people with this common type of ANCA-associated vasculitis (AAV) tended to…

About a quarter of people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) under maintenance treatment with rituximab experience relapses, mainly during the first two years. That’s according to a real-world study in Greece that looked at data from 101 people with GPA or MPA, the two most common…

People with ANCA-associated vasculitis (AAV) have an 83% higher risk of developing cardiovascular and cerebrovascular diseases (CCVD) relative to those without vasculitis, according to a review study that also showed the risk was significantly higher in the first two years after an AAV diagnosis. “These findings underline the importance…

Conduit Pharmaceuticals is planning to launch Phase 2a clinical trials to test its lead oral candidate AZD1656 in people with immune system disorders — specifically ANCA-associated vasculitis (AAV) as one indication. “With its potential to become a first-in-class therapy for autoimmune diseases, AZD1656 represents a significant leap forward…

Blood tests that look for the anti-neutrophil cytoplasmic autoantibodies (ANCAs) that cause ANCA-associated vasculitis (AAV) may help identify patients with kidney involvement, a study shows. Still, ANCA testing was not as accurate for this purpose as a kidney biopsy, wherein a small piece of kidney tissue is collected…

Researchers have identified a set of clinical red flags that could help detect eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV). Among the red flags are specific high-level thresholds of eosinophils, a type of immune cell, combined with other signs including asthma, nasal polyps,…

About 1 in 10 people with idiopathic interstitial pneumonia (IIP), a condition marked by lung scarring of an unknown cause, who test positive for antineutrophil cytoplasmic antibodies, or ANCAs, eventually develop ANCA-associated vasculitis (AAV), a study shows. These patients’ risk factors for AAV include testing positive for ANCAs against…